Lung Cancer Screening With Low Dose Computed Tomography in Patients With and Without Prior History of Cancer in the National Lung Screening Trial.


Journal

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235

Informations de publication

Date de publication:
06 2021
Historique:
received: 08 11 2020
revised: 06 01 2021
accepted: 02 02 2021
pubmed: 14 2 2021
medline: 8 7 2021
entrez: 13 2 2021
Statut: ppublish

Résumé

Patients with a prior history of cancer (PHC) are at increased risk of second primary malignancy, of which lung cancer is the most common. We compared the performance metrics of positive screening rates and cancer detection rates (CDRs) among those with versus without PHC. We conducted a secondary analysis of 26,366 National Lung Screening Trial participants screened with low dose computed tomography between August 2002 and September 2007. We evaluated absolute rates and age-adjusted relative risks (RRs) of positive screening rates on the basis of retrospective Lung CT Screening Reporting & Data System (Lung-RADS) application, invasive diagnostic procedure rate, complication rate, and CDR in those with versus without PHC using a binary logistic regression model using Firth's penalized likelihood. We also compared cancer type, stage, and treatment in those with versus without PHC. A total of 4.1% (n = 1071) of patients had PHC. Age-adjusted rates of positive findings were similar in those with versus without PHC (Baseline: PHC = 13.7% versus no PHC = 13.3%, RR [95% confidence interval (CI)]: 1.04 [0.88-1.24]; Subsequent: PHC = 5.6% versus no PHC = 5.5%, RR [95% CI]: 1.02 [0.84-1.23]). Age-adjusted CDRs were higher in those with versus without PHC on baseline (PHC=1.9% versus no PHC = 0.8%, RR [95% CI]: 2.51 [1.67-3.81]) but not on subsequent screenings (PHC = 0.6% versus no PHC = 0.4%, RR [95% CI]: 1.37 [0.99-1.93]). There were no differences in cancer stage, type, or treatment by PHC status. Patients with PHC may benefit from lung cancer screening, and with their providers, should be made aware of the possibility of higher cancer detection, invasive procedures, and complication rates on baseline lung cancer screening, but not on subsequent low dose computed tomography screening examinations.

Identifiants

pubmed: 33581343
pii: S1556-0864(21)01703-2
doi: 10.1016/j.jtho.2021.02.003
pmc: PMC8159850
mid: NIHMS1679650
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

980-989

Subventions

Organisme : NCI NIH HHS
ID : R01 CA212014
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA251686
Pays : United States

Informations de copyright

Copyright © 2021 International Association for the Study of Lung Cancer. All rights reserved.

Références

JAMA. 2016 Jun 7;315(21):2300-11
pubmed: 27179989
Lung Cancer. 2019 Jan;127:130-137
pubmed: 30642541
Lung Cancer. 2016 Aug;98:106-113
pubmed: 27393515
Radiology. 2011 Jan;258(1):243-53
pubmed: 21045183
CA Cancer J Clin. 2019 Sep;69(5):363-385
pubmed: 31184787
Br J Cancer. 2017 Mar 14;116(6):717-725
pubmed: 28196065
Cancer. 2015 Dec 15;121(24):4341-7
pubmed: 26372542
Ann Intern Med. 2019 Nov 5;171(9):623-632
pubmed: 31634914
J Thorac Oncol. 2016 Sep;11(9):1447-52
pubmed: 27223458
Cancer. 2016 Oct;122(19):3075-86
pubmed: 27377470
N Engl J Med. 2011 Aug 4;365(5):395-409
pubmed: 21714641
J Thorac Cardiovasc Surg. 2012 Jul;144(1):33-8
pubmed: 22710039
Thorax. 2007 May;62(5):386-90
pubmed: 16449263
Ann Intern Med. 2014 Mar 4;160(5):330-8
pubmed: 24378917
Clin Lung Cancer. 2017 Sep;18(5):543-550.e3
pubmed: 28412093
Ann Intern Med. 2015 Apr 7;162(7):485-91
pubmed: 25664444
Am J Respir Crit Care Med. 2018 Jul 15;198(2):e3-e13
pubmed: 30004250
PLoS Med. 2017 Apr 4;14(4):e1002277
pubmed: 28376113
Eur Radiol. 2021 Jan;31(1):458-467
pubmed: 32728771
Chest. 2019 Nov;156(5):965-971
pubmed: 31283920

Auteurs

Louise M Henderson (LM)

Department of Radiology, University of North Carolina, Chapel Hill, North Carolina; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina. Electronic address: Louise_Henderson@med.unc.edu.

Danielle D Durham (DD)

Department of Radiology, University of North Carolina, Chapel Hill, North Carolina.

Martin C Tammemägi (MC)

Department of Health Sciences, Brock University, St. Catharines, Ontario, Canada; Prevention and Cancer Control, Ontario Health (Cancer Care Ontario), Toronto, Ontario, Canada.

Thad Benefield (T)

Department of Radiology, University of North Carolina, Chapel Hill, North Carolina.

Mary W Marsh (MW)

Department of Radiology, University of North Carolina, Chapel Hill, North Carolina.

M Patricia Rivera (MP)

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH